Don’t miss – Page 175 – Endpoints News

SIGN UP

Intercept scores a mixed win on NASH Phase III sweepstakes, plans marketing pitch

4 years ago

The top 10 pipeline blowups, setbacks and snafus for H2 2018

4 years ago

AstraZeneca sweeps away the MedImmune name as CEO Soriot restructures R&D

4 years ago

Vas Narasimhan earned a big pay hike when he moved to the CEO's suite at Novartis

4 years ago

It's a flop: Gilead's top late-stage drug selonsertib flunked its first Phase III NASH trial

4 years ago

AbbVie jumps into the frenzied race for a BCMA/CD3 bispecific targeting multiple myeloma. Teneobio who?

4 years ago

Sanofi’s latest R&D remodeling spotlights what’s hot (bispecifics) and what’s not (CTLA-4) in oncology today

4 years ago

Sangamo shares take a big hit as investors react to setback for pioneering gene-editing tech

4 years ago

Basking in praise and a $4.2B GSK pact, Merck KGaA blueprints expansion plans for Boston-area R&D campus

4 years ago

After Tesaro buy, GSK wades deeper into cancer unveiling big immunotherapy deal with Germany's Merck

4 years ago

Gilead takes an $820M hit after axing a Kite CAR-T. Are billions more going to be incinerated?

4 years ago

'Most feared' activist investor in America has zeroed in on Bristol-Myers Squibb. Is he planning to derail the $74B Celgene buyout?

4 years ago

Pharma, we have a problem: New drugs can't cover the cost of Big Pharma's failures

4 years ago

Playing hardball, Bristol-Myers bought out a battered Celgene with last-minute terms sweetened in its own favor

4 years ago

‘Can we stop that work, can we delay that work?’ Bristol-Myers’ top execs outline their game plan for absorbing Celgene

4 years ago

That biotech unicorn you (pick love or hate) just spotlighted some intriguing mouse (yes) data on a triple mRNA cancer therapy

4 years ago

Roche pulls another major piece out of the wobbly Alzheimer's jenga, shuttering crenezumab PhIIIs

4 years ago

As Pfizer kills failed PhIII programs for Bavencio, where do they go from here in R&D?

4 years ago

Voyager bags a 'transformational' $1.8B gene therapy pact with Neurocrine

4 years ago

Disgraced at Vertex, Ian Smith’s career implosion ends with swift exile from biotech boards

4 years ago

Alexander Hardy tapped to head back to South San Francisco as the next CEO at Genentech

4 years ago

Vertex ousts longtime exec Ian Smith over unspecified code of conduct violations

4 years ago

KKR backs monster $300M raise to build up a new-model biotech — designed by Neil Kumar and MIT’s Andrew Lo

4 years ago

Editas founder Katrine Bosley abruptly steps aside from the helm, just ahead of historic CRISPR move

4 years ago

First page Previous page 172 173 174175176 177 178 Next page Last page